Mr. Risser was named President and Chief Executive Officer in August 2025 and previously served as Chief Operating Officer. Prior to joining us in 2009, Mr. Risser held the position of Senior Director, Business Development in the pharmaceutical group at Johnson & Johnson, where he worked from 2003 to 2009. Before Johnson & Johnson, Mr. Risser started and built a consulting practice that provided counsel to emerging life science companies in the United States and Europe. Earlier in his career, Mr. Risser held venture capital and investment banking positions with BA Venture Partners and Lehman Brothers Holdings Inc., respectively. Mr. Risser holds an M.B.A. from Stanford University and a B.A. from Yale University.

Mr. Karrels, Senior Vice President, Chief Financial Officer and Corporate Secretary, joined us in May 2008 and has over 25 years of experience in finance, with a significant portion of that time working for, or on behalf of, life sciences companies. Prior to joining us, he served as Executive Director of Finance at Jazz Pharmaceuticals, Inc., where he was responsible for the company’s financial planning and analysis and investor relations activities. Prior to joining Jazz Pharmaceuticals, Mr. Karrels was in the Global Healthcare Investment Banking Group at Merrill Lynch, serving most recently as a Director. Mr. Karrels holds an M.B.A. from Stanford University and a B.B.A. from the University of Notre Dame.

Dr. Bonvini, Senior Vice President, Research and Chief Scientific Officer, joined us in June 2003.  From 1985 to 2003, Dr. Bonvini was with the FDA in the Center for Biologics Evaluation and Research, or CBER, which is responsible for regulating therapeutic monoclonal antibodies and other proteins, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. From 1982 to 1984, Dr. Bonvini was a Visiting Fellow at the National Cancer Institute at the National Institutes of Health. Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.

Steve Harig, Senior Vice President, Human Resources, joined us in December 2023 and has over 20 years of experience in biotechnology companies. Prior to joining MacroGenics, Mr. Harig most recently held various human resources leadership roles in Emergent BioSolutions. Prior to Emergent, Mr. Harig was with MedImmune, the global biologics arm of AstraZeneca. From 2002 through 2013, Mr. Harig had positions of increasing responsibility in the MedImmune human resources department. Mr. Harig holds a B.S. from the University of Illinois.

Mr. Krishnaswamy, Senior Vice President, Business Development & Portfolio Planning, joined us in 2018. He is responsible for business development activities, including developing product strategy and portfolio planning, and has played a critical role in the closing of multiple high-value collaborations over the past several years. Prior to joining us, he spent six years in venture capital at Domain Associates, where he conducted early stage investing and new company creation. Prior to Domain Associates, Mr. Krishnaswamy spent six years at Abbott Labs within the cardiovascular division in various cross-functional leadership roles. 

Mr. Krishnaswamy earned his BSE in biomedical engineering with a concentration in computer science from Johns Hopkins University and his MBA from Haas School of Business at University of California, Berkeley.

Jeffrey Peters, Senior Vice President, General Counsel, joined us in August 2015. Before joining MacroGenics, Mr. Peters most recently served as Deputy General Counsel, Health, for the Biotechnology Innovation Organization (BIO), the leading national trade association for the biotechnology industry. While at BIO, Mr. Peters served as the primary legal counsel on health regulatory and related matters, including legal and policy matters affecting all aspects of biopharmaceutical product discovery, development, and delivery. Prior to BIO, Mr. Peters was with MedImmune, the global biologics arm of AstraZeneca. From 2005 through 2013, Mr. Peters had positions of increasing responsibility in the MedImmune legal department, culminating as Vice President and Deputy General Counsel. Mr. Peters was in private practice for almost a decade, joining MedImmune from the life sciences practice group at Latham & Watkins LLP, in Washington, D.C. Mr. Peters holds a J.D. from the University of Pennsylvania Law School and a B.A. in both Politics and Literature from Brandeis University.

Dr. Spitznagel, Senior Vice President, Technical Operations, joined us in 2013. He has overall responsibility for biopharmaceutical development and manufacturing of MacroGenics’ Fc-optimized monoclonal antibodies, DART^® molecules, and Antibody Drug Conjugates, as well as quality, supply chain, CMC project management, facilities and engineering. Prior to joining us, he was at Human Genome Sciences, most recently serving as Vice President of BioPharmaceutical Development, where he was responsible for oversight of Analytical Development, Formulation and Drug Delivery, Purification Sciences, and Fermentation and Cell Culture Sciences. Prior to joining HGS, Dr. Spitznagel was a Senior Scientist at Nabi from 1996-1998, and a Staff Engineer at Genetics Institute from 1992-1996. Dr. Spitznagel earned his BS in Chemical Engineering at M.I.T, and his Ph.D. in Chemical Engineering at the University of California, Berkeley.

Dr. Perabo, Vice President, Interim Head of Clinical Development, joined us in July 2025 and brings more than 20 years of global leadership experience in the biopharmaceutical industry, spanning discovery through late-stage development and commercialization. He has led over 40 clinical studies across more than 30 countries and has contributed to multiple successful global regulatory submissions and product approvals, including XTANDI® (enzalutamide), ORSERDU® (elacestrant), Myrbetriq® (mirabegron), and Vesomni®. Prior to joining us, Dr. Perabo held senior clinical and development leadership roles at Astellas Pharma, ESSA Pharmaceuticals, MAIA Biotechnology, and Tachyon Therapeutics, where he advanced a range of oncology and specialty programs encompassing small molecules, biologics, and gene therapies. He also serves on the Board of Directors of DVANT Pharma. 

Dr. Perabo earned his M.D. from the University of Munich and his Ph.D. in cancer biology, magna cum laude, from the same institution. He trained in surgery at the Technical University of Munich and the University of Freiburg, completed board certification in urology at Bonn University, and is a Fellow of the European Board of Urology (F.E.B.U.).

Beth Smith, Vice President, Controller and Treasurer, joined us in October 2013 and has over 35 years of experience in accounting and finance. Prior to joining us, Ms. Smith was the Director, Corporate Accounting at Human Genome Sciences. Before Human Genome Sciences, Inc. Ms. Smith held various accounting positions in publicly held companies after beginning her career with Ernst & Young. Ms. Smith holds a B.S. in Business Administration with a concentration in Accounting from Bucknell University and is a Certified Public Accountant-Inactive.